Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Amir Hossein Daneshmanesh(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Dan Grandér(Karolinska University Hospital), Katja Pokrovskaja Tamm(BioClinicum (Russia)), Håkan Mellstedt(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Mahmood Jeddi‐Tehrani(Academic Center for Education, Culture and Research), Sören Lehmann(Uppsala University), Fazel Shokri(Academic Center for Education, Culture and Research), Stefan Norin(Karolinska University Hospital), Hodjattallah Rabbani(Karolinska University Hospital), Anna Porwit(Lund University)
Cited by 83
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453